TY  - CHAP
M1  - Book, Section
TI  - Clinical Evaluation, Diagnosis, and Staging of Lung Cancer
A1  - Burks, A. Cole
A1  - Rivera, M. Patricia
A2  - Grippi, Michael A.
A2  - Antin-Ozerkis, Danielle E.
A2  - Dela Cruz, Charles S.
A2  - Kotloff, Robert M.
A2  - Kotton, Camille Nelson
A2  - Pack, Allan I.
PY  - 2023
T2  - Fishman’s Pulmonary Diseases and Disorders, 6e
AB  - Patients  who  present  with  suspected  lung  cancer  require  a  detailed  clinical  evaluation  followed  by  noninvasive  testing  and  invasive  procedures  to  establish  both  the  histopathologic  diagnosis  as  well  as  disease  stage.  Historically,  great  emphasis  has  been  placed  upon  the  differentiation  of  small-cell  lung  cancer  (SCLC)  from  non–small-cell  lung  cancer  (NSCLC).  SCLC,  which  accounts  for  13%  of  bronchogenic  carcinomas,  is  histologically  and  clinically  distinct  from  NSCLC.1  NSCLCs  comprise  clinically,  pathologically,  and  molecularly  diverse  tumors  that  respond  to  different  therapeutic  agents  based  on  specific  histologic  phenotypes  and  molecular  characteristics.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1195013061
ER  -